Translating Established Targets: Potent anti-Tumor Activity of a KAT6A/KAT6B Inhibitor PF-9363/CTx-648 in KAT6A dysregulated ER+ Breast Cancer

Time: 2:45 pm
day: Day Two


  • Understanding molecular dysregulation of KAT6A has been observed in several cancers, including amplifications in breast, lung, ovarian cancer along with oncogenic fusions in AML
  • Examining CTx-648 (PF-9363), a first-in-class potent KAT6A/KAT6B inhibitor that possess high selectivity versus other MYST family members (KAT7, KAT5, KAT8)
  • Learn how CTx-648 (PF-9363) inhibits expression of ESR1 expression leading to potent antitumor activity in ER+ breast cancer models